• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 22, 2022 at 10:32: AM
via Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.

article source
 




Top Bottom
Back
Quote